Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action

Journal of Medicinal Chemistry

Volumn 43, Issue 3, 2000, Pages 488-504

  De Lombaert, Stéphane ^a,b   Blanchard, Louis ^a   Stamford, Lisa B ^a   Tan, Jenny ^a   Wallace, Eli M ^a   Satoh, Yoshitaka ^a   Fitt, John ^a   Hoyer, Denton ^a   Simonsbergen, David ^a   Moliterni, John ^a   Marcopoulos, Nicholas ^a   Savage, Paula ^a   Chou, Mary ^a   Trapani, Angelo J ^a   Jeng, Arco Y ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NEUROGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 DIBENZOFURAN 3 YL 1 (1H TETRAZOL 5 YL)ETHYLAMINO]METHYLPHOSPHONIC ACID; 2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 DIBENZOFURAN 3 YL 2 (PHOSPHONOMETHYLAMINO)PROPIONIC ACID; CGS 34043; CGS 35066; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ASPARTIC ENDOPEPTIDASES; BENZOFURANS; BLOOD PRESSURE; ENDOTHELIN-1; ENDOTHELINS; ENZYME INHIBITORS; HUMANS; MALE; METALLOENDOPEPTIDASES; PHOSPHONIC ACIDS; PROTEIN PRECURSORS; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES;

EID: 0034628537     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990507o     Document Type: Article

References (45)

1. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (London) 1988, 332, 411-415.
2. Cheng, X.-M.; Nikam, S. S.; Doherty, A. M. Development of agents to modulate the effects of endothelin. Curr. Med. Chem. 1994, 1, 271-312.
3. Goto, K.; Kama, H.; Kasuya, Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn. J. Pharmacol. 1996, 72, 261-290.
4. Miyauchi, T.; Masaki, T. Pathophysiology of endothelin in the cardiovascular system. Annu. Rev. Physiol. 1999, 61, 391-415.
5. Battistini, B.; Dussault, P. Biosynthesis, distribution and metabolism of endothelins in the pulmonary system. Pulm. Pharmacol. Ther. 1998, 11, 79-88.
6. Brooks, D. P.; DePalma, P. D.; Gellai, M.; Nambi, P.; Ohlstein, E.; Elliott, J. D.; Gleason, J. G.; Ruffolo, R. R. Nonpeptide endothelin receptor antagonists. III. Effects of SB209670 and BQ123 on acute renal failure in anesthetized dogs. J. Pharmacol. Exp. Ther. 1994, 271, 769-775.
7. Lago, M. A.; Luengo, J. I.; Peishoff, C. E.; Elliott, J. D. Endothelin antagonists. Annu. Rep. Med. Chem. 1996, 31, 81-90.
8. (a) Jeng, A. Y.; De Lombaert, S. Endothelin-converting enzyme inhibitors. Curr. Pharm. Des. 1997, 3, 597-614.
9. (b) Loffler, B. M. ACE, NEP, ECE-1: Selective and combined inhibition. Curr. Opin. Cardiovasc. Pulm. Renal Invest. Drugs 1999, 1, 352-364.
10. Telemaque, S.; Emoto, N.; Dewit, D.; Yanagisawa, M. In vivo role of endothelin-converting enzyme-1 as examined by adenovirus-mediated overexpression in rats. J. Cardiovasc. Pharmacol. 1998, 31, S548-S550.
11. Turner, A. J.; Murphy, L. J. Molecular pharmacology of endothelin converting enzymes. Biochem. Pharmacol. 1996, 51, 91-102.
12. Davenport, A. P.; Kuc, R. E.; Plumpton, C.; Mockridge, J. W.; Barker, P. J.; Huskisson, N. S. Endothelin-converting enzyme in human tissues. Histochem. J. 1998, 30, 359-374.
13. Azarani, A.; Boileau, G.; Crine, P. Recombinant human endothelin-converting enzyme ECE-1b is located in an intracellular compartment when expressed in polarized Madin-Darby canine kidney cells. Biochem. J. 1998, 333, 439-448.
14. Turner, A. J.; Barnes, K.; Schweizer, A.; Valdenaire, O. Isoforms of endothelin-converting enzyme: why and where? Trends Pharmacol. Sci. 1998, 19, 483-486.
15. Yanagisawa, H.; Yanagisawa, M.; Kapur, R. P.; Richardson, J. A.; Williams, S. C.; Clouthier, D. E.; deWit, D.; Emoto, N.; Hammer, R. E. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development 1998, 125, 825-836.
16. Roques, B. P. Cell surface metallopeptidases involved in blood pressure regulation: structure, inhibition and clinical perspectives. Pathol. Biol. 1998, 46, 191-200.
17. Vemulapalli, S.; Chintala, M.; Stamford, A.; Walking, R.; Chiu, P.; Sybertz, E.; Fawzi, A. B. Renal effects of SCH 54470: a triple inhibitor of ECE, ACE, and NEP. Cardiovasc. Drug Rev. 1997, 15, 260-272.
18. Hay, D. W. P.; Goldie, R. G. Potential pathophysiological role of endothelin-1 in asthma. Drug News Perspect. 1998, 11, 411-418.
19. Fukami, T.; Hayama, T.; Amano, Y.; Nakamura, Y.; Arai, Y.; Matsuyama, K.; Yano, M.; Ishikawa, K. Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon. Bioorg. Med. Chem. Lett. 1994, 4, 1257-1262.
20. Keller, P. M.; Lee, C.-P.; Fenwick, A. E.; Atkinson, S. T.; Elliott, J. D.; DeWolf, W. E., Jr. Endothelin-converting enzyme: substrate specificity and inhibition by novel analogues of phosphoramidon. Biochem. Biophys. Res. Commun. 1996, 223, 372-378.
21. Takaishi, S.; Tuchiya, N.; Sato, A.; Negishi, T.; Takamatsu, Y.; Matsushita, Y.; Watanabe, T.; Iijima, Y.; Haruyama, H.; Kinoshita, T.; Tanaka, M.; Kodama, K. B-90063, a novel endothelin converting enzyme inhibitor isolated from a new marine bacterium, Blastobacter sp. SANK 71894. J. Antibiot. 1998, 51, 805-815.
22. Ahn, K.; Sisneros, A. M.; Herman, S. B.; Pan, S. M.; Hupe, D.; Lee, C.; Nikam, S.; Cheng, X.-M.; Doherty, A. M.; Schroeder, R. L.; Haleen, S. J.; Kaw, S.; Emoto, N.; Yanagisawa, M. Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem. Biophys. Res. Commun. 1998, 243, 184-190.
23. Massa, M. A.; Patt, W. C.; Ahn, K.; Sisneros, A. M.; Herman, S. B.; Doherty, A. Synthesis of novel substituted pyridines as inhibitors of endothelin converting enzyme-1 (ECE-1). Bioorg. Med. Chem. Lett. 1998, 8, 2117-2122.
24. Takahashi, T.; Kanda, T.; Inoue, M.; Sumino, H.; Kobayashi, I.; Iwamoto, A.; Nagai, R. Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Life Sci. 1998, 63, PL137-PL143.
25. Wada, A.; Tsutamoto, T.; Ohnishi, M.; Sawaki, M.; Fukai, D.; Maeda, Y.; Kinoshita, M. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: Comparison of effects with those of endothelin A receptor antagonism. Circulation 1999, 99, 570-577.
26. De Lombaert, S.; Ghai, R. D.; Jeng, A. Y.; Trapani, A. J.; Webb, R. L. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme. Biochem. Biophys. Res. Commun. 1994, 204, 407-412.
27. Caner, H. H.; Kwan, A.-L.; Arthur, A.; Jeng, A. Y.; Lappe, R. W.; Kassell, N. F.; Lee, K. S. Systemic administration of an inhibitor of endothelin-converting enzyme for attenuation of cerebral vasospasm following experimental subarachnoid hemorrhage. J. Neurosurg. 1996, 85, 917-922.
28. Kwan, A.-L.; Bavbek, M.; Jeng, A. Y.; Maniara, W.; Toyoda, T.; Lappe, R. W.; Kassell, N. F.; Lee, K. S. Prevention and reversal of cerebral vasospasm by an endothelin-converting enzyme inhibitor, CGS 26303, in an experimental model of subarachnoid hemorrhage. J. Neurosurg. 1997, 87, 281-286.
29. Kwan, A.-L.; Bavbek, M.; Jeng, A. Y.; Toyoda, T.; Kassell, N. F.; Lee, K. S. Attenuation of experimental subarachnoid hemorrhage-induced cerebral vasospasm by CGS 26303, an endothelin-converting enzyme inhibitor. J. Cardiovasc. Pharmacol. 1998, 31, S320-S322.
30. Shetty, S. S.; Savage, P.; Delgrande, D.; De Lombaert, S.; Jeng, A. Y. Characterization of CGS 31447, a potent and nonpeptidic endothelin-converting enzyme inhibitor. J. Cardiovasc. Pharmacol. 1998, 31, S68-S70.
31. De Lombaert, S.; Stamford, L. B.; Blanchard, L.; Tan, J.; Hoyer, D.; Diefenbacher, C. G.; Wei, D.; Wallace, E. M ; Moskal, M. A.; Savage, P.; Jeng, A. Y. Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11. Bioorg. Med. Chem. Lett. 1997, 7, 1059-1064.
32. Wallace, E. M.; Moliterni, J. A.; Moskal, M. A.; Neubert, A. D.; Marcopoulos, N.; Stamford, L. B.; Trapani, A. J.; Savage, P.; Chou, M.; Jeng, A. Y. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme. J. Med. Chem. 1998, 41, 1513-1523.
33. Satoh, Y.; De Lombaert, S.; Marcopoulos, N.; Moliterni, J.; Moskal, M.; Tan, J.; Wallace, E. Synthesis of tetrazole analogues of a-amino acids by alkylation of a Schiff base of α-aminomethyltetrazole. Tetrahedron Lett. 1998, 39, 3367-3370.
34. De Lombaert, S.; Blanchard, L.; Tan, J.; Sakane, Y; Berry, C.; Ghai, R. D. Non-peptidic inhibitors of neutral endopeptidase 24.11. 1. Discovery and optimization of potency. Bioorg. Med. Chem. Lett. 1995, 5, 145-150.
35. Biller, S. A.; Forster, C. The synthesis of isoprenoid (phosphinylmethy)phosphonates. Tetrahedron 1990, 46, 6645-6658.
36. Akermark, B.; Eberson, L.; Jonsson, E.; Pettersson, E. Palladium-promoted cyclization of diphenyl ether, diphenylamine, and related compounds. J. Org. Chem. 1975, 40, 1365-1367.
37. Okamoto, S. New N-acyl-3-substituted-phenylalanine derivatives. EP 0284632, 1988.
38. De Lombaert, S.; Blanchard, L.; Tan, J.; Trapani, A. J. Non-peptidic inhibitors of neutral endopeptidase 24.11. 2. Design of orally active phosphonate prodrugs and pharmacological evaluation. Bioorg. Med. Chem. Lett. 1995, 5, 151-154.
39. Shapiro, M. J.; Archinal, A. E.; Jarema, M. A. Chiral purity determination by proton NMR spectroscopy. Novel use of 1,1′-binaphthyl-2,2'-diylphosphoric acid. J. Org. Chem. 1989, 54, 5826-5828.
40. De Lombaert, S.; Erion, M. D.; Tan, J.; Blanchard, L.; El-Chehabi, L.; Ghai, R.; Sakane, Y.; Berry, C.; Trapani, A. J. N-Phosphonomethyl dipeptides and their phophonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. J. Med. Chem. 1994, 37, 498-511.
41. De Lombaert, S.; Tan, J.; Stamford, L. J.; Sakane, Y.; Berry, C.; Ghai, R. D. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme by N-phosphonomethyl and N-carboxyalkyl dipeptides. Bioorg. Med. Chem. Lett. 1994, 4, 2715-2720.
42. Ha, H. I.; Nam, G. S.; Park, K. P. A new route to N-substituted aminomethylphosphonates. Bull. Korean Chem. Soc. 1990, 11, 485-486.
43. Bird, J.; De Mello, R. C.; Harper, G. P.; Hunter, D. J.; Karran, E. H.; Markwell, R. E.; Miles-Williams, A. J.; Rahman, S. S.; Ward, R. W. Synthesis of novel N-phosphonoalkyl dipeptide inhibitors of human collagenase. J. Med. Chem. 1994, 37, 158-169.
44. W. Maniara, E. Walter (Novartis), personal communication.
45. Sansom, C. E.; Hoang, M. V.; Turner, A. J. Molecular modelling and site-directed mutagenesis of the active site of endothelin-converting enzyme. Prot. Eng. 1998, 11, 1235-1241.